BenevolentAI, a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.
Novel target for Heart Failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca
...
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA H100 Tensor Core GPUs interconnected by NVIDIA Quantum-2 InfiniBand networking. This NVIDIA-powered AI supercomputer results in four times...
Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between care and research, announced a collaboration with the Association of Cancer Care Centers (ACCC), a powerful network of more than 40,000 multidisciplinary practitioners from cancer care...
Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, announced the expansion of its artificial intelligence (AI) capabilities in the Beacon platform. Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market...
Dyno Therapeutics announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.
Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The capacity to design...
Sorcero, a leading Google Cloud healthcare and life science ecosystem partner, has developed a revolutionary generative AI (gen AI) solution for creating plain language summaries (PLS) of complex scientific content. This innovative approach aims to bridge the gap between scientific research and public understanding, making critical information more accessible...
VantAI, a leader in generative AI and drug discovery, announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs. He brings over 20 years...
Nimbus Therapeutics, LLC, a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology. In this role, Dr. Scheuber will lead the company’s clinical development strategy...
Cache DNA, Inc., a life sciences company revolutionizing biological sample and data storage infrastructure, announced the closing of its seed round. The team raised an undisclosed amount from notable investors, including Climate Capital Bio, Exor Ventures, Hawktail, LifeX Ventures, Pillar VC, and Trousdale Ventures, including support from Illumina and...
ACTO announced the launch of TalkTRx™, the first product designed to give reps access to marketing assets with layered context so they can deliver accurate presentations and more personal with health professionals. ACTO's TalkTRx is developed as part of the company's AI-powered Intelligent Field Excellence (IFE) platform, purpose-built for...
